MPNs

Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.

In an interview with&nbsp;Targeted Oncology, Tania Jain,&nbsp;<a>MBBS,</a>&nbsp;discussed the role of transplant as treatment of patients with myelofibrosis and the challenges that remain in this space. She also spoke to the treatment options for patients with graft-versus-host-disease.

Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.

A report from the Canadian Myeloproliferative Neoplasm Group has outlined different patterns of treatment failure from JAK inhibitor therapy in patients with myelofibrosis. The report, published in JCO Oncology Practice, suggests management practices for each pattern of response.

The FDA has granted 2 orphan drug designations to ALPN-101 for both the prevention and treatment of acute graft-versus-host disease, according to a press release from Alpine Immune Sciences.

Ruxolitinib was found to be safe and effective for long-term treatment of patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, according to the 5-year follow-up data from the phase III RESPONSE trial, recently published in&nbsp;The Lancet Haematology.&nbsp;

Ropeginterferon alfa-2b improved responses overtime in patients with polycythemia vera who presented predominantly without splenomegaly compared with hydroxyurea, according to findings from the phase III PROUD-PV clinical trial and its extension study, CONTINUATION-PV.

Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.

At the 24th Annual International Congress on Hematologic Malignancies, host by Physicians&rsquo; Education Resource&acirc;, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.

Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with&nbsp;myelofibrosis-associated anemia.

In an interview with&nbsp;Targeted Oncology,&nbsp;Aaron T. Gerds, MD, MS, discussed interim results from a phase II study of luspatercept as a treatment of anemia in patients with myelofibrosis, which he presented at the 2019 Annual Society of Hematology Annual Meeting.

Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.

The combination therapy of panobinostat and ruxolitinib was found to be safe and effective for the treatment of patients with primary myelofibrosis and post-polycythemia vera related myelofibrosis, and post essential thrombocythemia related myelofibrosis, according to the results of a dose-escalating, &nbsp;phase I trial, which was published in Leukemia Research.

The combination of APR-246 and azacytidine was granted Breakthrough Therapy Designation by the FDA for the treatment of myelodysplastic syndromes with susceptible TP53 mutations, Aprea Therapeutics, Inc, developer of APR-246, announced in a press release.

Ruben Mesa, MD, discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms.

A new phase III trial has found that luspatercept reduced the severity of anemia in patients with transfusion-refractory, lower-risk myelodysplastic syndromes with ring sideroblasts. Results from the MEDALIST trial, which included data from 65 sites in 11 countries, were published recently in the New England Journal of Medicine.

Ruxolitinib plus low-dose&nbsp;pegylated interferon-a2 improved peripheral blood cell counts, bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis, according to the 2-year, end-of-study results of the phase II COMBI study, which were recently published in Haematologica.

In an interview with&nbsp;Targeted Oncology, Ruben Mesa, MD, discussed the findings from the pooled analysis of fedratinib at full dose in patients with myelofibrosis who had baseline platelet counts below 100 X 10⁹/L. He also highlighted other agents and therapies that appear promising for the treatment of patients with myeloproliferative neoplasms.